<DOC>
	<DOCNO>NCT01366612</DOCNO>
	<brief_summary>This single institution study fludarabine busulfan versus fludarabine , busulfan low dose total body irradiation patient undergo allogeneic stem cell transplantation . A study population 80 subject enrol The John Theurer Cancer Center Hackensack University Medical Center . Subjects eligible receive allogeneic hematopoietic stem cell transplantation accord eligibility criterion consent enrol . Subjects randomly assign receive one 2 condition regimen : fludarabine busulfan , fludarabine busulfan low dose total body irradiation ( TBI ) . Subjects follow 1 year post transplantation ass relapse rate arm transplant-related toxicity . The combination fludarabine busulfan current standard care patient myeloid malignancy ( AML , CML myeloproliferative disorder , MDS ) undergo allogeneic transplantation HUMC . In study compare randomize fashion standard regimen regimen fludarabine , busulfan TBI .</brief_summary>
	<brief_title>PRO # 1278 : Fludarabine Busulfan vs. Fludarabine , Busulfan Total Body Irradiation</brief_title>
	<detailed_description>This single institution study fludarabine busulfan versus fludarabine , busulfan low dose total body irradiation patient undergo allogeneic stem cell transplantation . A study population 80 subject enrol The John Theurer Cancer Center Hackensack University Medical Center . Subjects eligible receive allogeneic hematopoietic stem cell transplantation accord eligibility criterion consent enrol . Subjects randomly assign receive one 2 condition regimen : fludarabine busulfan , fludarabine busulfan low dose total body irradiation ( TBI ) . Subjects follow 1 year post transplantation ass relapse rate arm transplant-related toxicity . The combination fludarabine busulfan current standard care patient myeloid malignancy ( myelogenous leukemia , chronic myelogenous leukemia , myeloproliferative disorder , myelodysplastic syndrome ) undergo allogeneic transplantation HUMC . In study compare randomize fashion standard regimen regimen fludarabine , busulfan TBI . Primary Objective The primary objective compare relapse rate 1 year patient myeloid malignancy receive regimen . Secondary Objectives The secondary objective compare toxicity regimen</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Diagnosis acute myelogenous leukemia , chronic myelogenous leukemia , myeloproliferative disorder , myelodysplastic syndrome Any stage disease consider transplantation Have suitable relate unrelated donor ( Section 3.3 ) Age ≥18 &lt; 70 yr KPS ≥70 % Recovery hematologic nonhematology toxicity previous therapy . Diagnosis acute myelogenous leukemia , myeloproliferative disorder , myelodysplastic syndrome Chemotherapy radiotherapy within 14 day initiate treatment study exception lenalidomide , decitabine , azacitidine , imatinib mesylate , dasatinib , nilotinib hydrochloride hydroxyurea Prior doseintense therapy require HSC support within 56 day initiate treatment study Uncontrolled bacterial , viral , fungal parasitic infection Uncontrolled CNS metastasis Known amyloid deposition heart Organ dysfunction LVEF &lt; 40 % cardiac failure responsive therapy FVC , FEV1 , DLCO &lt; 50 % predict and/or receive supplementary continuous oxygen Evidence hepatic synthetic dysfunction , total bilirubin &gt; 2x AST &gt; 3x ULN Measured creatinine clearance &lt; 20 ml/min Karnofsky score &lt; 70 % Life expectancy limit another comorbid illness Diagnosed treat another malignancy within 3 year enrollment , exception complete resection basal cell carcinoma squamous cell carcinoma skin , situ malignancy , lowrisk prostate cancer curative therapy Female subject pregnant breastfeeding ( woman ) unwilling use acceptable birth control method ( men woman ) twelve month treatment . Confirmation subject pregnant must establish negative serum βhuman chorionic gonadotropin ( βhCG ) pregnancy test result obtain screening . Pregnancy test require postmenopausal surgically sterilize woman . Documented hypersensitivity fludarabine melphalan bortezomib , boron mannitol component formulation Patients unable unwilling provide consent Myocardial infarction within 6 month prior enrollment New York Heart Association ( NYHA ) Class III IV heart failure ( see section 8.4 ) , uncontrolled angina , severe uncontrolled ventricular arrhythmia , electrocardiographic evidence acute ischemia active conduction system abnormality . Prior study entry , ECG abnormality screen document investigator medically relevant Patient receive investigational drug 14 day enrollment Serious medical psychiatric illness likely interfere participation clinical study Donor Inclusion Exclusion Criteria Donor HLA 6/6 ( HLAA , B , DrB1 ) relate donor 7/8 ( HLAA , B , C , DrB1 ) unrelated donor Related donor evaluate accordance HUMC standard practice guideline evaluation management allogeneic donor Unrelated donor identify , evaluate , manage accordance National Marrow Donor Program standard Age ≥18 &lt; 70 yr KPS ≥70 % Willing donate bone marrow use standard technique peripheral blood HSC leukapheresis Have adequate vein apheresis agree placement central venous catheter ( femoral , subclavian ) donate peripheral blood HSC Donor Exclusion Criteria Identical twin Female donor pregnant breastfeed Infection HIV viral hepatitis ( B C ) Known allergy filgrastim Current serious systemic illness Uncontrolled bacterial , viral , fungal infection Receiving experimental therapy investigational agent History cancer treat basal cell cancer skin carcinoma situ cervix . Cancer treat curative intent &gt; 5 yrs donation review casebycase basis principal investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Allogeneic Stem Cell Transplant</keyword>
	<keyword>AML</keyword>
	<keyword>CML</keyword>
	<keyword>MDS</keyword>
</DOC>